Provided by Tiger Trade Technology Pte. Ltd.

iShares Genomics Immunology and Healthcare ETF

42.72
+1.072.57%
Post-market: 42.970.2500+0.59%19:59 EDT
Volume:219.40K
Turnover:9.26M
Market Cap:318.26M
PE:- -
High:42.86
Open:41.64
Low:41.44
Close:41.65
52wk High:42.97
52wk Low:23.90
Shares:7.45M
Float Shares:7.45M
Volume Ratio:0.69
T/O Rate:2.94%
Dividend:0.28
Dividend Rate:0.65%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

From Lilly Deal to Market Darling: Inside Ginkgo's 120% Monthly Run

Bellwether Stocks Movement
·
58 mins ago

Trump: Thanks Howard Kessler for senior healthcare innovation

Trump's Truth Social latest posts
·
35 mins ago

Moderna (MRNA) Names A New COO, Is The Rally Already Priced In?

Simply Wall St.
·
1 hour ago

Moderna COO Juan Andres Files Initial Beneficial Ownership Statement

Reuters
·
5 hours ago

Moderna Inc. Stock Rises 6.9%, Outperforms Peers

Dow Jones
·
7 hours ago

Twist Bioscience CEO Emily Leproust Disposes of $8.77 Million in Common Shares

Reuters
·
7 hours ago

IntegraGen Faces Judicial Liquidation as Court Weighs Takeover Bids

TIPRANKS
·
10 hours ago

Moderna Inc Stock (MRNA) Moved Up by 5.71% on Oct 5: What Investors Need To Know

TradingKey
·
10 hours ago

Vortex Energy Launches Study on Natural Hydrogen and Helium at Robinsons River Salt Project

TIPRANKS
·
11 hours ago

Cboe data shows mixed options sentiment in Moderna with shares up 0.52%

TIPRANKS
·
Yesterday

Revolution Medicines Starts Phase 3 Trial of Rasonque-Zoldonrasib Combo in First-Line Metastatic RAS G12D Pancreatic Cancer

Reuters
·
Yesterday

Revolution Medicines Begins Treating Patients in Phase 3 Rasolute 309 Trial Evaluating Rasonque™ (Daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic Ras G12d Pancreatic Cancer

THOMSON REUTERS
·
Yesterday

Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease

GlobeNewswire
·
Yesterday

Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026

GlobeNewswire
·
Yesterday

Revolution Medicines, Inc. : Leerink Partners Resumes Coverage with Outperform Rating; Price Target $288

THOMSON REUTERS
·
Yesterday

Gene Editing, Protein Electron Transfer, Self-Assembled Monolayers 鈥?Which Will Win the Nobel Prize in Chemistry? Two Experts Share Their Predictions

Deep News
·
Oct 04

Twist Bioscience (TWST) Rallies As Growth Narrative Tests Whether The Stock Is Already Pricey

Simply Wall St.
·
Oct 04

ADPT, MRNA, CRWV, NBIS, JAZZ trending with analysts

TIPRANKS
·
Oct 03

Cboe data shows mixed options sentiment in Moderna with shares down 1.81%

TIPRANKS
·
Oct 02

Moderna Shares Reverse Course, Last Down 1.3%

THOMSON REUTERS
·
Oct 02